Sophia’s BENLYSTA treatment

Hypothetical patient profile. May not be representative of all patients.

video transcript

CHARLOTTE: When her doctor suggested adding BENLYSTA, we were just really hopeful it would make a difference and help her get back to being a kid again.

[ON-SCREEN TEXT: Sophia*]

[ON-SCREEN TEXT: Results may vary.]

[ON-SCREEN TEXT: * Hypothetical patient profile. May not be representative of all BENLYSTA patients.]

CHARLOTTE: She’s been taking BENLYSTA infusions for about 10 months now and I think it is making a difference. Her rash has cleared up and she’s having far fewer bad days keeping her from activities.

SOPHIA: At first, I didn’t want infusions because I was really scared of needles. But it’s ok now. My mom and the nurses hold my hand and then I close my eyes, and the needle part is over pretty fast.

[ON-SCREEN TEXT: Sophia’s BENLYSTA IV dosing: 10 mg/kg every 2 weeks for the first 3 infusions and every 4 weeks thereafter.]

[ON-SCREEN TEXT: Results may vary.]

CHARLOTTE: As Sophia’s symptoms improved, our entire family has felt the difference. We hadn’t really realized how much we were avoiding places and events out of fear that Sophia would wake up not feeling well.

SOPHIA: I’m seeing my friends way more these days – even having sleepovers on weekends. And I know my mom worries less now, so that makes me happy!

VOICEOVER: IMPORTANT PRODUCT INFORMATION: For patients on standard therapy: Aged 5 years and older with active systemic lupus erythematosus or active lupus nephritis. Not for use in severe active central nervous system lupus. Reported: serious & sometimes fatal infections; progressive multifocal leukoencephalopathy; acute hypersensitivity reactions, including anaphylaxis & death, and infusion-related reactions; and, depression & suicidality. Avoid live vaccines. Common adverse reactions: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, & injection site reactions.

[ON-SCREEN TEXT: IMPORTANT PRODUCT INFORMATION
For patients on standard therapy: Aged 5+ and older with active SLE or active lupus nephritis. Not for use in severe active CNS lupus. Reported: serious & sometimes fatal infections; PML; acute hypersensitivity reactions, including anaphylaxis & death, and infusion-related reactions; and, depression & suicidality. Avoid live vaccines. Common adverse reactions: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, & injection site reactions.

Please see the full Important Safety Information for BENLYSTA on this page. Please click the link to view full Prescribing Information, including Medication Guide, for BENLYSTA.]

[ON-SCREEN TEXT:
Benlysta
(belimumab)
Intravenous Use 120 mg/Vial
Subcutaneous Use 200 mg/mL

Trademarks are owned or licensed to the GSK group of companies. ©2024 GSK or licensor. BELVID230034 January 2024. Produced in USA.

[ON-SCREEN TEXT: GSK]

[ON-SCREEN TEXT: Ahead Together]

You may also like

See Sophia's diagnosis story

Review Sophia's initial treatment

Icon: Computer

Join us for a live webinar

Learn more